Over the past 10 years, a number of novel serum biomarkers have been reported that may improve the diagnosis of myocarditis and predict progression to cardiomyopathy/DCM and heart failure including sera soluble ST2 (sST2), myoglobin, IL-17-associated miRs, Th17-associated cytokines, and Th17 vs. Treg ratios (55, 142, 173–175). This evidence concerns the gene IL17A and familial dilated cardiomyopathy.